FindMyKOL

Lorenzo Zaffiri, MD;, PhD

Basic profile

Emory University

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionAtlanta, GA · SoutheastSpecialtyPulmonary DiseaseFocusRespiratory
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Lorenzo Zaffiri is a Respiratory physician affiliated with Emory University. OpenAlex indexes 94 publications with 1,068 citations (h-index 16); ClinicalTrials.gov lists 1 registered study matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
94publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

1,068citations

Citations across these publications.

16h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
4companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • KAMADA LTD.
    Program year20249 payments
    $5,381
  • Boehringer Ingelheim Pharmaceuticals, Inc.
    Program year20231 payment
    $1,438
  • Inari Medical, Inc.
    Program year20231 payment
    $207
All 5 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    42.2%
    Macrolide Antimicrobial17.5%
    Azithromycin100%
    Part D≥76 patients
    Short-acting sulfonamides15.6%
    Sulfamethoxazole-Trimethoprim100%
    Part D≥79 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    22.1%
    Proton pump inhibitor8.9%
    Pantoprazole Sodium79%Omeprazole13%Lansoprazole7%
    Part D<11 patients
    Corticosteroid7.7%
    Prednisone100%
    Part D≥44 patients

    + 6 more classes in this area

  • Nervous system

    11.7%
    Gabapentinoids7%
    Gabapentin92%Pregabalin8%
    Part D<11 patients
    SSRI2.8%
    Trazodone Hcl58%Escitalopram Oxalate23%Citalopram Hbr18%
    Part D<11 patients

    + 1 more class in this area

Where care is delivered (Part B)67.2% facility · 32.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”